Search research articles
Contact Us
Filters
Showing results (171-180 of 225) with videos related to
Page
of 23
Sort By:
Journal of the American College of Cardiology
|
July 2, 2021
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
John W Eikelboom, Deepak L Bhatt, Keith A A Fox, et al.
Stroke
|
May 7, 2026
Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial
Ashkan Shoamanesh, Stuart J Connolly, Andrew M Demchuk, et al.
The Lancet. Neurology
|
October 3, 2018
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial
Scott E Kasner, Balakumar Swaminathan, Pablo Lavados, et al.
Stroke
|
September 20, 2021
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial
Mukul Sharma, Eric E Smith, Lesly A Pearce, et al.
Circulation
|
January 23, 2019
Stroke Outcomes in the COMPASS Trial
Mukul Sharma, Robert G Hart, Stuart J Connolly, et al.
JAMA Neurology
|
October 19, 2020
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial
Ashkan Shoamanesh, Robert G Hart, Stuart J Connolly, et al.
Annals of Neurology
|
November 28, 2014
Early cerebral small vessel disease and brain volume, cognition, and gait
Eric E Smith, Martin O'Donnell, Gilles Dagenais, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|
June 5, 2019
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial
Robert G Hart, Roland C Veltkamp, Patrick Sheridan, et al.
JAMA Neurology
|
July 7, 2020
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial
Roland Veltkamp, Lesly A Pearce, Eleni Korompoki, et al.
Journal of the American Heart Association
|
May 7, 2017
Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment
Eric E Smith, Alicja Cieslak, Philip Barber, et al.
Page
of 23
Search research articles
Search
Showing results (171-180 of 225) with videos related to
Sort By:
Page
of 23
Journal of the American College of Cardiology
|
July 2, 2021
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
John W Eikelboom, Deepak L Bhatt, Keith A A Fox, et al.
Stroke
|
May 7, 2026
Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial
Ashkan Shoamanesh, Stuart J Connolly, Andrew M Demchuk, et al.
The Lancet. Neurology
|
October 3, 2018
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial
Scott E Kasner, Balakumar Swaminathan, Pablo Lavados, et al.
Stroke
|
September 20, 2021
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial
Mukul Sharma, Eric E Smith, Lesly A Pearce, et al.
Circulation
|
January 23, 2019
Stroke Outcomes in the COMPASS Trial
Mukul Sharma, Robert G Hart, Stuart J Connolly, et al.
JAMA Neurology
|
October 19, 2020
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial
Ashkan Shoamanesh, Robert G Hart, Stuart J Connolly, et al.
Annals of Neurology
|
November 28, 2014
Early cerebral small vessel disease and brain volume, cognition, and gait
Eric E Smith, Martin O'Donnell, Gilles Dagenais, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|
June 5, 2019
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial
Robert G Hart, Roland C Veltkamp, Patrick Sheridan, et al.
JAMA Neurology
|
July 7, 2020
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial
Roland Veltkamp, Lesly A Pearce, Eleni Korompoki, et al.
Journal of the American Heart Association
|
May 7, 2017
Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment
Eric E Smith, Alicja Cieslak, Philip Barber, et al.
Page
of 23